A-426 - Gene Signatures predict immune-related skin adverse events in melanoma patients

Autor: Mallardo, D., Fordellone, M., Bailey, M., White, A., Simeone, E., Festino, L., Vanella, V., Trojaniello, C., Vitale, M.G., Ottaviano, M., Sparano, F., Facchini, B.A., Cavalcanti, E., Church, S., Caracò, C., Cesano, A., Warren, S., Chiodini, P., Ascierto, P.A.

Publikováno v: In EJC Skin Cancer 2024 2 Supplement 1

The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis

Autor: Rossi, C.R. ^*, Mozzillo, N., Maurichi, A., Pasquali, S., Quaglino, P., Borgognoni, L., Solari, N., Piazzalunga, D., Mascheroni, L., Giudice, G., Mocellin, S., Patuzzo, R., Caracò, C., Ribero, S., Marone, U., Santinami, M.

Publikováno v: In Annals of Oncology January 2014 25(1):240-246

1076O Primary analysis of the EORTC 1208 Minitub trial: Prospective registry of sentinel node (SN) positive melanoma patients with minimal SN tumor burden

Autor: van Akkooi, A.C.J., Massi, D., Kicinski, M., Brackley, P., Gruenhagen, D., Rastrelli, M., Signh, M., Peach, H., Peric, B., Caracò, C., Boecxstaens, V., Moncrieff, M., Marreaud, S.I., Louis, R., de Schaetzen, G., Koljenovic, S., van de Wiel, B., Mandalà, M., Cook, M., Eggermont, A.M.M.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S712-S712

1163P CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy

Autor: Mallardo, D., Fordellone, M., White, A., Ottaviano, M., Sparano, F., Bailey, M., Facchini, B.A., Ong, S., Maiolino, P., Caracò, C., Church, S.E., Cavalcanti, E., Warren, S., Budillon, A., Cesano, A., Simeone, E., Chiodini, P., Ascierto, P.A.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S693-S693

BRAF testing techniques in the management of patients with advanced malignant melanoma: a real world comparative study

Autor: Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V, Fedeli MA, Sini MC, Palomba G, Pisano M, Melanoma Unit of Sassari (MUS), Italian Association for Cancer Research (AIRC) Study Group, Ascierto PA, Caracò C, Lissia A, Cossu A, Palmieri G, Italian Melanoma Intergroup (IMI).

Publikováno v: IMI Congresso 2020, online, 07-09/11/2020
info:cnr-pdr/source/autori:Colombino M, Rozzo C, Paliogiannis P, Casula M, Manca A, Doneddu V, Fedeli MA, Sini MC, Palomba G, Pisano M, Melanoma Unit of Sassari (MUS), Italian Association for Cancer Research (AIRC) Study Group, Ascierto PA, Caracò C, Lissia A, Cossu A, Palmieri G, Italian Melanoma Intergroup (IMI)./congresso_nome:IMI Congresso 2020/congresso_luogo:online/congresso_data:07-09%2F11%2F2020/anno:2020/pagina_da:/pagina_a:/intervallo_pagine

Malignant melanoma (MM) is one of the deadliest skin cancers. BRAF mutation testing plays a predominant role in the management of MM patients, because modern targeted therapies essentially consist of inhibitors of BRAF. BRAF V600 mutation must be det

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::3ea24a4e8cebd86648f139dface88782
http://www.cnr.it/prodotto/i/442941